

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adam Blumenthal
Date of last notice	27 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C> (an entity controlled by Mr Blumenthal)
Date of change	2 July 2019
No. of securities held prior to change	<p>Direct (Adam Blumenthal)</p> <p>1 Fully Paid Ordinary Share</p> <p>Indirect (Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>)</p> <p>5,500,000 Fully Paid Ordinary Shares</p> <p>750,000 CPHPERR4 Performance Rights, subject to vesting conditions</p> <p>2,750,000 Listed CPHO Options (exercisable at \$0.80 on or before 21 August 2020)</p>
Class	Fully Paid Ordinary Shares (issued upon the vesting of CPHPERR4 Performance Rights)

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	750,000 Fully Paid Ordinary Shares
Number disposed	750,000 CPHPERR4 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>Direct (Adam Blumenthal)</p> <p>1 Fully Paid Ordinary Share</p> <p>Indirect (Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C>)</p> <p>6,250,000 Fully Paid Ordinary Shares</p> <p>2,750,000 Listed CPHO Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Vesting and conversion of CPHPERR4 Performance Rights.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Boaz Wachtel
Date of last notice	27 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	International Water and Energy Savers Ltd (an entity controlled by Mr Wachtel)
Date of change	02 July 2019
No. of securities held prior to change	Indirect (International Water and Energy Savers Ltd) 6,800,000 Fully Paid Ordinary Shares 1,500,000 CPHPERR4 Performance Rights, subject to vesting conditions 800,000 CPHPERR6 Performance Rights, subject to vesting conditions 800,000 CPHPERR7 Performance Rights, subject to vesting conditions 3,000,000 Listed CPHO Options (exercisable at \$0.80 on or before 21 August 2020)

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Class	Fully Paid Ordinary Shares (issued upon the vesting of CPHPERR4 Performance Rights)
Number acquired	1,500,000 Fully Paid Ordinary Shares
Number disposed	1,500,000 CPHPERR4 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Indirect (International Water and Energy Savers Ltd) 8,300,000 Fully Paid Ordinary Shares 800,000 CPHPERR6 Performance Rights, subject to vesting conditions 800,000 CPHPERR7 Performance Rights, subject to vesting conditions 3,000,000 Listed CPHO Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Vesting and conversion of CPHPERR4 Performance Rights.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Ellingford
Date of last notice	27 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	02 July 2019
No. of securities held prior to change	1,100,000 Fully Paid Ordinary Shares 250,000 CPHPERR4 Performance Rights, subject to vesting conditions 100,000 CPHPERR13 Performance Rights, subject to vesting conditions 550,000 Listed CPHO Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)
Class	Fully Paid Ordinary Shares (issued upon the vesting of CPHPERR4 Performance Rights)
Number acquired	250,000 Fully Paid Ordinary Shares
Number disposed	250,000 CPHPERR4 Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	1,350,000 Fully Paid Ordinary Shares 100,000 CPHPERR13 Performance Rights, subject to vesting conditions 550,000 Listed CPHO Options (<i>exercisable at \$0.80 on or before 21 August 2020</i>)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Vesting and conversion of CPHPERR4 Performance Rights.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CRESO PHARMA LIMITED
ABN	89 609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Miri Halperin Wernli
Date of last notice	27 August 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Jorge Wernli <WHP Management Consulting AC> (spouse of Miri Halperin Wernli)
Date of change	02 July 2019
No. of securities held prior to change	<p>Direct (Miriam Halperin Wernli) 8,250,000 Fully Paid Ordinary Shares 1,750,000 CPHPERR4 Performance Rights* 1,250,000 CPHPERR8 Performance Rights* 1,250,000 CPHPERR9 Performance Rights* 4,072,950 Listed CPHO Options (\$0.80, 21 Aug 2020)</p> <p>Indirect (Jorge Wernli <WHP Management Consulting AC>) 150,000 Fully Paid Ordinary Shares 150,000 CPHPERR14 Performance Rights* 75,000 Listed CPHO Options</p> <p>*Subject to vesting conditions</p>

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Class	Fully Paid Ordinary Shares (issued upon the vesting of CPHPERR4, CPHPERR8, CPHPERR9 and CPHPERR14 Performance Rights)
Number acquired	4,400,000 Fully Paid Ordinary Shares
Number disposed	1,750,000 CPHPERR4 Performance Rights 1,250,000 CPHPERR8 Performance Rights 1,250,000 CPHPERR9 Performance Rights 150,000 CPHPERR14 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Direct (Miri Halperin Wernli) 12,500,000 Fully Paid Ordinary Shares 4,072,950 Listed CPHO Options (\$0.80, 21 Aug 2020) Indirect (Jorge Wernli <WHP Management Consulting AC>) 300,000 Fully Paid Ordinary Shares 75,000 Listed CPHO Options (\$0.80, 21 Aug 2020)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Vesting and conversion of CPHPERR4, CPHPERR8, CPHPERR9 and CPHPERR14 Performance Rights.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.